Reshaping the Treatment Landscape in the Department of Veteran Affairs: Immunotherapy in Non-Melanoma Skin Cancer
Risk Assessment and the Role of Immunotherapy in Patients with cSCC
Pre-test
Questions marked with a
*
are required
100%
Contact Information
First Name
Last Name
Email Address
Which of the following can be used for assessing risk for cSCC recurrence, metastasis or death?
American Joint Committee on Cancer (AJCC) staging manual – 8 th edition
Brigham Womens Hospital alternative staging system
Tübingen system
All of the above
Cemiplimab may be considered in patients who
Are considered borderline resectable
Are considered unresectable
Carry a high morbidity with surgical intervention
All of the above
Done
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close